These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 26854819

  • 1. Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression.
    Gupta R, Gupta K, Tripathi AK, Bhatia MS, Gupta LK.
    Pharmacology; 2016; 97(3-4):184-8. PubMed ID: 26854819
    [Abstract] [Full Text] [Related]

  • 2. Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder.
    Tafseer S, Gupta R, Ahmad R, Jain S, Bhatia MS, Gupta LK.
    Pharmacol Biochem Behav; 2021 Jan; 200():173073. PubMed ID: 33186562
    [Abstract] [Full Text] [Related]

  • 3. Effect of Agomelatine and Fluoxetine on HAM-D Score, Serum Brain-Derived Neurotrophic Factor, and Tumor Necrosis Factor-α Level in Patients With Major Depressive Disorder With Severe Depression.
    Gupta K, Gupta R, Bhatia MS, Tripathi AK, Gupta LK.
    J Clin Pharmacol; 2017 Dec; 57(12):1519-1526. PubMed ID: 28833192
    [Abstract] [Full Text] [Related]

  • 4. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression.
    Kang RH, Chang HS, Wong ML, Choi MJ, Park JY, Lee HY, Jung IK, Joe SH, Kim L, Kim SH, Kim YK, Han CS, Ham BJ, Lee HJ, Ko YH, Lee MS, Lee MS.
    J Psychopharmacol; 2010 Dec; 24(12):1755-63. PubMed ID: 19493959
    [Abstract] [Full Text] [Related]

  • 5. Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD).
    Katsuki A, Yoshimura R, Kishi T, Hori H, Umene-Nakano W, Ikenouchi-Sugita A, Hayashi K, Atake K, Iwata N, Nakamura J.
    CNS Spectr; 2012 Sep; 17(3):155-63. PubMed ID: 22883353
    [Abstract] [Full Text] [Related]

  • 6. Changes of serum concentrations of brain-derived neurotrophic factor (BDNF) during treatment with venlafaxine and mirtazapine: role of medication and response to treatment.
    Deuschle M, Gilles M, Scharnholz B, Lederbogen F, Lang UE, Hellweg R.
    Pharmacopsychiatry; 2013 Mar; 46(2):54-8. PubMed ID: 22961097
    [Abstract] [Full Text] [Related]

  • 7. Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation.
    Giese M, Beck J, Brand S, Muheim F, Hemmeter U, Hatzinger M, Holsboer-Trachsler E, Eckert A.
    J Psychiatr Res; 2014 Dec; 59():1-7. PubMed ID: 25258340
    [Abstract] [Full Text] [Related]

  • 8. Sertraline with desvenlafaxine and sertraline with mirtazapine as treatment initiation in MDD patients with moderate to severe depression and effect on inflammatory markers.
    Arockiaraj N, Gupta R, Ahmad R, Halder S, Bhatia MS.
    Int J Psychiatry Clin Pract; 2024 Mar; 28(1):9-16. PubMed ID: 38019131
    [Abstract] [Full Text] [Related]

  • 9. Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features.
    Patas K, Penninx BW, Bus BA, Vogelzangs N, Molendijk ML, Elzinga BM, Bosker FJ, Oude Voshaar RC.
    Brain Behav Immun; 2014 Feb; 36():71-9. PubMed ID: 24140302
    [Abstract] [Full Text] [Related]

  • 10. Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine.
    Ghosh R, Gupta R, Bhatia MS, Tripathi AK, Gupta LK.
    Asian J Psychiatr; 2015 Dec; 18():37-41. PubMed ID: 26514447
    [Abstract] [Full Text] [Related]

  • 11. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study.
    Haapasalo-Pesu KM, Vuola T, Lahelma L, Marttunen M.
    J Child Adolesc Psychopharmacol; 2004 Dec; 14(2):175-84. PubMed ID: 15319015
    [Abstract] [Full Text] [Related]

  • 12. Mirtazapine acutely inhibits salivary cortisol concentrations in depressed patients.
    Laakmann G, Hennig J, Baghai T, Schüle C.
    Ann N Y Acad Sci; 2004 Dec; 1032():279-82. PubMed ID: 15677428
    [Abstract] [Full Text] [Related]

  • 13. Influence of mirtazapine on salivary cortisol in depressed patients.
    Laakmann G, Hennig J, Baghai T, Schüle C.
    Neuropsychobiology; 2003 Dec; 47(1):31-6. PubMed ID: 12606843
    [Abstract] [Full Text] [Related]

  • 14. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT, Shelton RC, Bao W, Guico-Pabia CJ.
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan 03; 48():86-91. PubMed ID: 24096053
    [Abstract] [Full Text] [Related]

  • 15. Effect of mirtazapine on thyroid hormones in adult patients with major depression.
    Gambi F, De Berardis D, Sepede G, Campanella D, Galliani N, Carano A, La Rovere L, Salini G, Penna L, Cicconetti A, Spinella S, Quartesan R, Salerno RM, Ferro FM.
    Int J Immunopathol Pharmacol; 2005 Jan 03; 18(4):737-44. PubMed ID: 16388723
    [Abstract] [Full Text] [Related]

  • 16. Mirtazapine does not influence tetrahydrodeoxycorticosterone levels in depressed patients.
    Schüle C, Baghai TC, di Michele F, Eser D, Pasini A, Romeo E, Rupprecht R.
    World J Biol Psychiatry; 2010 Mar 03; 11(2 Pt 2):308-13. PubMed ID: 20218794
    [Abstract] [Full Text] [Related]

  • 17. High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors.
    Yukimasa T, Yoshimura R, Tamagawa A, Uozumi T, Shinkai K, Ueda N, Tsuji S, Nakamura J.
    Pharmacopsychiatry; 2006 Mar 03; 39(2):52-9. PubMed ID: 16555165
    [Abstract] [Full Text] [Related]

  • 18. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study.
    Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, MacDonald MM, Gary KA.
    Biol Psychiatry; 2000 Jul 01; 48(1):75-8. PubMed ID: 10913511
    [Abstract] [Full Text] [Related]

  • 19. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
    Fawcett J, Barkin RL.
    J Clin Psychiatry; 1998 Mar 01; 59(3):123-7. PubMed ID: 9541155
    [Abstract] [Full Text] [Related]

  • 20. Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home.
    Roose SP, Nelson JC, Salzman C, Hollander SB, Rodrigues H, Mirtazapine in the Nursing Home Study Group.
    Curr Med Res Opin; 2003 Mar 01; 19(8):737-46. PubMed ID: 14687445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.